Asthma control, lung function, symptoms, and corticosteroid sparing after omalizumab initiation in patients with allergic asthma

Background: Omalizumab is approved in patients with moderate-to-severe allergic asthma with symptoms uncontrolled, despite the mainstay therapy. Objective: Electronic medical records (EMR) were used to increase the knowledge of omalizumab effectiveness in a real-world setting. Methods: Patients with uncontrolled moderate-to-severe allergic asthma, ages >= 12 years old, initiated on omalizumab (index date), with >= 12 months of pre-and postindex data, were identified in an EMR data base. An Asthma Control Test score (>= 20 is considered well controlled), forced expiratory volume in 1 second as a percentage of the predicted value (< 80% considered below normal), symptoms, and oral corticosteroid (OCS) and inhaled corticosteroid (ICS) use were compared in the 12-month post-versus the preindex period with univariate generalized estimating equations adjusted for repeated measurements. Results: A total of 208 patients (mean +/- standard deviation[SD] age, 41 +/- 19 years; 64.9% women; 71.2% white; and with a mean +/- SD serum total immunoglobulin E level of 455.4 +/- 644.7 IU/mL) were identified. In the post-versus preindex period, the patients were significantly more likely to have well-controlled asthma (odds ratio [OR] 1.72 [95% confidence interval {CI}, 1.11-2.64]) and less likely to have a lung function value below normal (nonsignificant) after omalizumab initiation. The patients experienced significantly less coughing (OR 0.66 [95% CI, 0.49-0.91]), shortness of breath (OR 0.60 [95% CI, 0.44-0.83]), and wheezing (OR 0.59 [95% CI, 0.43-0.81]), with no improvement in chest tightness. A significantly lower likelihood of new OCS prescriptions (OR 0.58 [95% CI, 0.41-0.82]) was observed. A lower likelihood of new high-and medium-dose ICS prescriptions was nonsignificant. Conclusion: Omalizumab was associated with beneficial effects on asthma control and symptoms, and the likelihood of requiring new OCS prescriptions. An observed trend of improved lung function and lower likelihood of requiring high-and medium-dose ICS did not reach statistical significance.